<?xml version='1.0' encoding='utf-8'?>
<document id="19629022"><sentence text="Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities."><entity charOffset="0-14" id="DDI-PubMed.19629022.s1.e0" text="Desvenlafaxine" /><entity charOffset="19-30" id="DDI-PubMed.19629022.s1.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s1.e0" e2="DDI-PubMed.19629022.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s1.e0" e2="DDI-PubMed.19629022.s1.e1" /></sentence><sentence text="Identification of potential pharmacokinetic drug-drug interactions is an important step in clinical drug development" /><sentence text="We assessed and compared the drug-drug interaction potential of desvenlafaxine and venlafaxine, based on their inhibitory potency on human cytochrome P450 (CYP) and P-glycoprotein (P-gp) activities in vitro"><entity charOffset="64-78" id="DDI-PubMed.19629022.s3.e0" text="desvenlafaxine" /><entity charOffset="83-94" id="DDI-PubMed.19629022.s3.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s3.e0" e2="DDI-PubMed.19629022.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s3.e0" e2="DDI-PubMed.19629022.s3.e1" /></sentence><sentence text="" /><sentence text="Reversible inhibition of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and mechanism-based inhibition of CYP2C9, CYP2C19, CYP2D6, and CYP3A activity by desvenlafaxine and venlafaxine were determined in human liver microsomes"><entity charOffset="167-181" id="DDI-PubMed.19629022.s5.e0" text="desvenlafaxine" /><entity charOffset="186-197" id="DDI-PubMed.19629022.s5.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s5.e0" e2="DDI-PubMed.19629022.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s5.e0" e2="DDI-PubMed.19629022.s5.e1" /></sentence><sentence text="Whether these drugs were substrates for efflux or inhibitors of P-gp were determined in Caco-2 monolayers" /><sentence text="" /><sentence text="Desvenlafaxine and venlafaxine showed little or no reversible inhibition of various CYP enzymes (concentration that inhibits 50% [IC50] or inhibition constant [Ki] ~ or &gt;100 muM)"><entity charOffset="0-14" id="DDI-PubMed.19629022.s8.e0" text="Desvenlafaxine" /><entity charOffset="19-30" id="DDI-PubMed.19629022.s8.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s8.e0" e2="DDI-PubMed.19629022.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s8.e0" e2="DDI-PubMed.19629022.s8.e1" /></sentence><sentence text=" In addition, neither drug acted as a mechanism-based inhibitor of CYP2C9, CYP2C19, CYP2D6, or CYP3A as they did not reduce the IC50 value for any of these enzymes in the presence of preincubations with or without a nicotinamide adenine dinucleotide phosphate-regenerating system"><entity charOffset="216-259" id="DDI-PubMed.19629022.s9.e0" text="nicotinamide adenine dinucleotide phosphate" /></sentence><sentence text=" Desvenlafaxine and venlafaxine showed little inhibition of P-gp activity (IC50 values &gt;250 muM) and did not act as substrates (efflux ratios &lt;2) for efflux in Caco-2 monolayers"><entity charOffset="1-15" id="DDI-PubMed.19629022.s10.e0" text="Desvenlafaxine" /><entity charOffset="20-31" id="DDI-PubMed.19629022.s10.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s10.e0" e2="DDI-PubMed.19629022.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s10.e0" e2="DDI-PubMed.19629022.s10.e1" /></sentence><sentence text="" /><sentence text="Considering in vitro and available clinical data, desvenlafaxine and venlafaxine appear to have low potential for pharmacokinetic drug-drug interactions via inhibiting the metabolic clearance of concomitant drugs that are substrates of various CYP enzymes, in particular CYP2D6"><entity charOffset="50-64" id="DDI-PubMed.19629022.s12.e0" text="desvenlafaxine" /><entity charOffset="69-80" id="DDI-PubMed.19629022.s12.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s12.e0" e2="DDI-PubMed.19629022.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s12.e0" e2="DDI-PubMed.19629022.s12.e1" /></sentence><sentence text=" In addition, these data suggest that desvenlafaxine and venlafaxine exhibit little potential for pharmacokinetic interactions with concomitant drugs that are substrates or inhibitors of P-gp"><entity charOffset="38-52" id="DDI-PubMed.19629022.s13.e0" text="desvenlafaxine" /><entity charOffset="57-68" id="DDI-PubMed.19629022.s13.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.19629022.s13.e0" e2="DDI-PubMed.19629022.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19629022.s13.e0" e2="DDI-PubMed.19629022.s13.e1" /></sentence><sentence text="" /></document>